1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

  • October 2017
  • 37 pages
  • ID: 1105426
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

Summary
Alzheimer’s disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide.

To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) to diagnose dementia, and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria to diagnose AD.

In the 7MM, our epidemiologists forecast an increase in the total prevalent cases of AD from around 10.6 million total prevalent cases in 2016 to around 13.7 total prevalent cases in 2026, at an annual growth rate (AGR) of nearly 3% during the forecast period. Among the 7MM, the US will have the highest number of total prevalent cases of AD throughout the forecast period, while the UK will have the lowest.

Similarly, our epidemiologists forecast that the total prevalent cases of MCI in the 7MM will increase from over 28 million total prevalent cases in 2016 to around 34.5 million total prevalent cases in 2026 at an AGR of about 2%. Among the 7MM, the US will have the highest number of total prevalent cases of MCI throughout the forecast period, while Spain will have the lowest.

The report "EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends for AD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the total prevalent cases of AD (diagnosed and undiagnosed) segmented by sex, age (ages 60 years and older), and severity in these markets. Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases of MCI segmented by sex and age (ages 60 years and older) in these markets.

Scope
- The Alzheimer’s Disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of AD (diagnosed and undiagnosed) segmented by sex, age (ages 60 years and older), and severity in these markets. Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age (ages 60 years and older) in these markets.
- The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The Alzheimer’s Disease EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global AD market.
- Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
- Understand severity of prevalent AD cases and total prevalent cases of MCI.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($3995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019

  • $ 3500
  • June 2019

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019SummaryDual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein ...

Ulcerative Colitis: Epidemiology Forecast to 2026 - Update

Ulcerative Colitis: Epidemiology Forecast to 2026 - Update

  • $ 3995
  • April 2019

Ulcerative Colitis: Epidemiology Forecast to 2026 - UpdateSummaryUlcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by long-lasting inflammation and ulcers (sores) in the lining ...

Insulin Like Growth Factor I - Pipeline Review, H1 2019

Insulin Like Growth Factor I - Pipeline Review, H1 2019

  • $ 3500
  • June 2019

Insulin Like Growth Factor I - Pipeline Review, H1 2019SummaryAccording to the recently published report ’Insulin Like Growth Factor I - Pipeline Review, H1 2019’; Insulin Like Growth Factor I (Mechano ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on